Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Share Repurchase Program - Amount Remaining

Share Repurchase Program - Amount Remaining at other companies

Baxter International logo
Baxter InternationalBAX
——

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's share repurchase program - amount remaining.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's share repurchase program - amount remaining?
Cumberland Pharmaceuticals (CPIX) reported share repurchase program - amount remaining of $2.1M in Q1 2026.
How has Cumberland Pharmaceuticals's share repurchase program - amount remaining changed year-over-year?
Cumberland Pharmaceuticals's share repurchase program - amount remaining decreased by 4.5% year-over-year, from $2.2M to $2.1M.